Efficacy of Adding Locoregional Therapy in ATZ/BEV-Treated Patients with Stable HCC
Authors:
- Atsushi HosuiAHAtsushi Hosui
- Naoko HayataNHNaoko Hayata
- Tomohide KurahashiTKTomohide Kurahashi
- Akane NamikiANAkane Namiki
- Akino OkamotoAOAkino Okamoto
- Kazuki AochiKAKazuki Aochi
- Munehiro AshidaMAMunehiro Ashida
- Takafumi TanimotoTTTakafumi Tanimoto
- Hiroki MuraiHMHiroki Murai
- Kohsaku OhnishiKOKohsaku Ohnishi
- Motohiro HiraoMHMotohiro Hirao
- Takuya YamadaTYTakuya Yamada
Open Access
Abstract
Background/Objectives: Combination therapy with atezolizumab and bevacizumab (ATZ/BEV) is extremely effective and yields a high response rate in patients with hepatocellular carcinoma (HCC). In this study, the efficacy of adding locoregional therapy to ATZ/BEV in patients with stable disease (SD) HCC was investigated. Methods: One hundred five HCC patients who were treated with ATZ/BEV or lenvatinib (LEN) as first-line chemotherapy for unresectable HCC were evaluated on the basis of the modified RECIST criteria. SD patients whose initial antitumor effect was achieved received locoregional therapy, and the overall survival (OS) rate was assessed. Results: This study included 58 ATZ/BEV-treated participants and 47 LEN-treated participants. Twenty-eight SD patients (ATZ/BEV) and 20 SD patients (LEN) were identified. OS was significantly greater in ATZ/BEV-treated patients who also received locoregional therapy than in those who did not receive this additional therapy (p = 0.0343), whereas there was no difference between LEN-treated patients who also received locoregional therapy and those who did not. The locoregional therapy consisted of transcatheter arterial chemoembolization (TACE) and/or radiofrequency ablation (RFA). When assessing the add-on effect of TACE and/or RFA in the SD patients treated with ATZ/BEV, five patients were found to achieve CR. Conclusions: The addition of locoregional therapy, such as TACE/RFA, was found to affect SD patients. When a response is limited during ATZ/BEV therapy, it is important to consider the therapeutic option of adding locoregional therapy, as this additional treatment may contribute to improved prognosis via immune modulation.Keywords
This publication has 29 references indexed in Scilit:
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinomaNature Communications, 2016
- Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinomaMolecular Medicine Reports, 2015
- Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinomaHepatology, 2012
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cellsNature, 2011
- Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSeminars in Liver Disease, 2010
- Myeloid-derived suppressor cells as regulators of the immune systemNature Reviews Immunology, 2009
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunityBritish Journal of Cancer, 2006
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996